Various clinical trials have explored the use of anti-CTLA-4 monoclonal antibodies in conjunction with anti-PD-1 antibodies in recurrent GBM (NCT03233152, NCT02794883) [104]. This evidence concerns the gene PDCD1 and glioblastoma.